Tag: MM

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

byKathleen Lau

January 14, 2021

#VisualAbstract Administering bortezomib on a weekly basis VS twice weekly basis does not significantly affect progression-free survival (PFS) or overall survival (OS) in Vrd first-line therapy for multiple myeloma (bortezomib, lenalidomide, and dexamethasone)

byKathleen Lau

January 1, 2021

#VisualAbstract GIMEMMA-MMY-3006: Bortezomib, Thalidomide, and Dexamethasone (VTD) Followed By Stem-Cell Transplantation Improves Long-Term Survival Outcomes in Newly Diagnosed Multiple Myeloma (MM)

byKathleen Lau

December 25, 2020

Check out the original article from the Lancet Haematology here.

#VisualAbstract Melphalan 200mg/m2 Versus Reduced Doses of Melphalan in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

byKathleen Lau

December 18, 2020

Page 2 of 2 Prev 1 2

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result